Eisai Inc. today announced that LUSEDRA(TM) (fospropofol disodium) Injection is now available for use by persons trained in the administration of general anesthesia. LUSEDRA, an aqueous solution, is an intravenous sedative-hypnotic agent indicated for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures. The U.S. Food and Drug Administration (FDA) approved LUSEDRA in December 2008. LUSEDRA is designated as a Schedule IV drug.
"We are pleased to offer the anesthesiology community a new option for their patients undergoing sedation," said Randi Fain, MD, FCCP, Director, Medical Affairs, Oncology and Institutional Care, Eisai Inc. "LUSEDRA will play an important role in the Eisai institutional care portfolio."